as 07-26-2024 4:00pm EST
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
Founded: | 1967 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 11.0M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 9.8K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -4.65 | EPS Growth: | N/A |
52 Week Low/High: | $1.73 - $3.21 | Next Earning Date: | 08-07-2024 |
Revenue: | $3,406,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Wool Kyle Michael | DOMH | President | May 29 '24 | Buy | $2.20 | 5,000 | $11,000.00 | 27,750 | SEC Form 4 |
Hayes Anthony | DOMH | CEO | May 29 '24 | Buy | $2.40 | 3,482 | $8,356.80 | 223,146 | SEC Form 4 |
Hayes Anthony | DOMH | CEO | May 29 '24 | Buy | $2.25 | 1,158 | $2,605.50 | 219,664 | SEC Form 4 |
Wool Kyle Michael | DOMH | President | Apr 8 '24 | Buy | $2.99 | 4,250 | $12,694.75 | 22,750 | SEC Form 4 |
Wool Kyle Michael | DOMH | President | Apr 8 '24 | Buy | $2.99 | 4,250 | $12,694.75 | 13,750 | SEC Form 4 |
Hayes Anthony | DOMH | CEO | Apr 4 '24 | Buy | $2.62 | 3,944 | $10,339.20 | 102,748 | SEC Form 4 |
Hayes Anthony | DOMH | CEO | Apr 4 '24 | Buy | $2.88 | 13,500 | $38,823.30 | 116,248 | SEC Form 4 |
Wool Kyle Michael | DOMH | President | Apr 4 '24 | Buy | $2.90 | 9,500 | $27,503.45 | 18,500 | SEC Form 4 |
Wool Kyle Michael | DOMH | President | Apr 4 '24 | Buy | $2.84 | 9,500 | $27,007.55 | 9,500 | SEC Form 4 |
Devall Christopher Franklin | DOMH | COO | Dec 26 '23 | Buy | $2.55 | 7,000 | $17,863.30 | 30,033 | SEC Form 4 |
Wool Kyle Michael | DOMH | President | Dec 26 '23 | Buy | $2.60 | 5,000 | $12,996.50 | 9,000 | SEC Form 4 |
Hayes Anthony | DOMH | CEO | Dec 20 '23 | Buy | $2.00 | 70,000 | $140,168.00 | 98,804 | SEC Form 4 |
Hayes Anthony | DOMH | CEO | Dec 12 '23 | Buy | $2.00 | 2,000 | $4,002.40 | 26,804 | SEC Form 4 |
Hayes Anthony | DOMH | CEO | Dec 12 '23 | Buy | $2.00 | 2,000 | $4,009.80 | 28,804 | SEC Form 4 |
Wool Kyle Michael | DOMH | Director10% Owner | Dec 12 '23 | Buy | $2.02 | 2,000 | $4,036.60 | 2,000 | SEC Form 4 |
Wool Kyle Michael | DOMH | Director10% Owner | Dec 12 '23 | Buy | $2.04 | 2,000 | $4,085.60 | 4,000 | SEC Form 4 |
Devall Christopher Franklin | DOMH | COO | Nov 30 '23 | Buy | $2.28 | 1,000 | $2,277.80 | 23,033 | SEC Form 4 |
Devall Christopher Franklin | DOMH | COO | Nov 28 '23 | Buy | $2.26 | 1,000 | $2,259.00 | 22,033 | SEC Form 4 |
Wool Kyle Michael | DOMH | Director10% Owner | Nov 27 '23 | Buy | $2.20 | 1,000 | $2,199.90 | 24,000 | SEC Form 4 |
Hayes Anthony | DOMH | CEO | Nov 22 '23 | Buy | $2.09 | 1,323 | $2,764.94 | 23,323 | SEC Form 4 |
Hayes Anthony | DOMH | CEO | Nov 22 '23 | Buy | $2.16 | 1,481 | $3,200.44 | 24,804 | SEC Form 4 |
Wool Kyle Michael | DOMH | Director | Nov 20 '23 | Buy | $2.05 | 2,000 | $4,103.40 | 23,000 | SEC Form 4 |
Hayes Anthony | DOMH | CEO | Nov 16 '23 | Buy | $1.97 | 2,500 | $4,915.75 | 22,000 | SEC Form 4 |
DOMH Breaking Stock News: Dive into DOMH Ticker-Specific Updates for Smart Investing
ACCESSWIRE
3 months ago
Insider Monkey
3 months ago
PR Newswire
4 months ago
PR Newswire
4 months ago
PR Newswire
5 months ago
PR Newswire
5 months ago
PR Newswire
5 months ago
PR Newswire
5 months ago
The information presented on this page, "DOMH Dominari Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.